The purpose of this study is to establish the long-term safety and efficacy of Biogeneric Epoetin, the attainability of therapeutic target for anaemia management, and the impact of Epoetin treatment on long-term health outcome and its cost effectiveness.

Start Date01 Aug 2005

Sponsor / Collaborator

Malaysia Ministry of Health

NCT00322413 / CompletedPhase 3IIT

Efficacy and Safety of Epoetin Omega in Patients Undergoing Regular Dialysis. Part II: Comparative Trial Versus Epoetin Alfa

The two epoetins, Epoetin alfa, a well established drug to treat renal anemia and Epoetin Omega, that differs from Epoetin alfa in the sugar moiety of the molecule were compared in regard of efficacy and safety to treat end stage renal disease anemia. Study hypothesis was that Epoetin Omega is non-inferior to Epoetin alfa in correcting renal anemia in dialysis patients. A 12-weeks randomized comparative efficacy study was performed including 77 end stage renal disease patients (epoetin omega:n=39, epoetin alfa: n=38). In the intent-to-treat analysis, average weekly difference in hemoglobin versus baseline value was higher in omega-treated patients: 1.94+-0.81 vs. 1.23+-0.62 g/dl. The unadjusted and adjusted omega-alfa differences were 0.71 g/dl (95%CI 0.38 to 1.04; p<0.001) and 0.78 g/dl (0.49 to 1.08;p<0.001), respectively. Average weekly epoetin dose was lower in the omega group: 87+-25 vs. 108+-21 IU/kg. The unadjusted and adjusted omega-alfa differences were -21IU/kg (-32 to -11; p<0.001) and -24IU/kg (-35 to -13; p<0.001), respectively. Epoetins were comparably well tolerated. In dialysis patients, subcutaneous epoetin omega apparently provides a greater anti-anemic effect per administered dose (IU) than epoetin alfa.

Start Date01 Jan 1997

Sponsor / Collaborator-

100 Clinical Results associated with Epoetin beta biosimilar(Abbott Laboratories)

100 Translational Medicine associated with Epoetin beta biosimilar(Abbott Laboratories)

100 Patents (Medical) associated with Epoetin beta biosimilar(Abbott Laboratories)

Literatures (Medical) associated with Epoetin beta biosimilar(Abbott Laboratories)

01 Jul 2024·Clinical Pharmacology & Therapeutics

Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis

Article

Author: Park, Haesuk ; Desai, Raj ; Shukla, Ashutosh M ; Riaz, Munaza ; Jeon, Nakyung ; Mohandas, Rajesh ; Smith, Steven M ; Unigwe, Ikenna

Both short‐acting (epoetin alfa or beta) and long‐acting (darbepoetin alfa or PEG‐epoetin) erythropoiesis‐stimulating agents (ESAs) are commonly prescribed for patients with kidney failure undergoing maintenance hemodialysis. We compared the risks of major adverse cardiovascular events (MACE) and of all‐cause mortality associated with receipt of short‐ vs. long‐acting ESAs. This retrospective cohort analysis included Medicare hemodialysis beneficiaries aged ≥ 18 years in the United States Renal Data System from January 2015 to December 2017. We included adults who survived > 90 days after initiating hemodialysis and received either short‐ or long‐acting ESAs. Outcomes were MACE (first occurrence of stroke, acute myocardial infarction, or cardiovascular‐related mortality) and all‐cause mortality. After stabilized inverse probability of treatment weighting, Cox proportional hazards regression models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for each outcome. Of 68,607 patients (mean age: 65 years, 45% females), 33,658 (49%) received long‐acting ESAs and 34,949 (51%) received short‐acting ESAs. There was no difference in the risk of MACE associated with receipt of short‐ vs. long‐acting ESAs (HR: 1.02 (95% CI: 0.98–1.08)). However, long‐acting (vs. short‐acting) ESA receipt was associated with a lower risk of all‐cause mortality (HR: 0.91 (95% CI: 0.87–0.96)). Compared with short‐acting ESAs, long‐acting ESAs were associated with a lower risk of all‐cause mortality, with no difference in the risk of MACE. Future studies with a longer follow‐up are needed to confirm these findings.

01 Nov 2011·Therapeutische Umschau

Wachstumsfaktoren - Erythropoetine

Article

Author: Hoffmann, Moritz ; Schwenger, Vedat

01 Jul 2003·Tumori JournalQ4 · MEDICINE

Utilizzo di Epoetina nei Pazienti Neoplastici Linee Guida dell'Asco e dell'ash per La Pratica Clinica Basate sull'Evidenza

Q4 · MEDICINE

Review

Author: Del Mastro, Lucia

News (Medical) associated with Epoetin beta biosimilar(Abbott Laboratories)

14 Sep 2022

·www.prnewswire.com

Erythropoietin Stimulating Agents Market to register USD 4.74 Bn growth - Technavio

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Technavio has been monitoring the Erythropoietin Stimulating Agents Market, operating under the health care industry. The report estimates the market to register an incremental growth of USD 4.74 billion, at a CAGR of 8.9% during the forecast period. The report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Request the Latest Free sample report . Technavio has announced its latest market research report titled Erythropoietin Stimulating Agents Market by Type and Geography - Forecast and Analysis 2022-2026 The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Competitors have to focus on differentiating their product offerings with unique value propositions to strengthen their foothold in the market. Market vendors also have to leverage the existing growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. 3SBio Inc., Akebia Therapeutics Inc., Amgen Inc., Biocon Ltd., Biosidus SA, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., LG Chem Ltd., Pieris Pharmaceuticals Inc., Reliance Industries Ltd., Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd. are among some of the major market participants. The presence of a large pool of CKD patients has been instrumental in driving the growth of the market. However, stringent government regulations might hamper the market growth. Buy Sample Report. Erythropoietin Stimulating Agents Market Segmentation Based on geographic segmentation, 42% of the market's originated from North America during the forecast period. In addition, the Epoetin Alfa category led the growth under the type segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the superfood powders market size. Type Epoetin Alfa Epoetin Beta Darbepoetin Alfa Others Geography North America Europe Asia Rest Of World (ROW) Erythropoietin Stimulating Agents Market Scope Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The erythropoietin stimulating agents market report covers the following areas: Erythropoietin Stimulating Agents Market Size Erythropoietin Stimulating Agents Market Trends Erythropoietin Stimulating Agents Market Industry Analysis This study identifies the growing number of CKD dialysis centers in developing economies as one of the prime reasons driving the Erythropoietin Stimulating Agents Market growth during the next few years. Download Free Sample Report. Erythropoietin Stimulating Agents Market Key Highlights CAGR of the market during the forecast period Detailed information on factors that will assist erythropoietin stimulating agents market growth during the next five years Estimation of the erythropoietin stimulating agents market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the erythropoietin stimulating agents market Analysis of the market's competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of the erythropoietin stimulating agents market, vendors Related Reports Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography - Forecast and Analysis 2022-2026: The stem cell umbilical cord blood (UCB) market share is expected to increase by $ 1.47 bn from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 16.87%. Pregabalin Market by Application and Geography - Forecast and Analysis 2022-2026: The pregabalin market share is expected to increase by USD 153.03 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 3.74%. Browse for Technavio " Health Care " Research Reports Table of Contents: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 Epoetin alfa - Market size and forecast 2021-2026 Exhibit 28: Chart on Epoetin alfa - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Epoetin alfa - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Epoetin alfa - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Epoetin alfa - Year-over-year growth 2021-2026 (%) 5.4 Epoetin beta - Market size and forecast 2021-2026 Exhibit 32: Chart on Epoetin beta - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Epoetin beta - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Epoetin beta - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Epoetin beta - Year-over-year growth 2021-2026 (%) 5.5 Darbepoetin alfa - Market size and forecast 2021-2026 Exhibit 36: Chart on Darbepoetin alfa - Market size and forecast 2021-2026 ($ million) Exhibit 37: Data Table on Darbepoetin alfa - Market size and forecast 2021-2026 ($ million) Exhibit 38: Chart on Darbepoetin alfa - Year-over-year growth 2021-2026 (%) Exhibit 39: Data Table on Darbepoetin alfa - Year-over-year growth 2021-2026 (%) 5.6 Others - Market size and forecast 2021-2026 Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million) Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million) Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%) Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%) 5.7 Market opportunity by Type Exhibit 44: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 46: Chart on Market share by geography 2021-2026 (%) Exhibit 47: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 48: Chart on Geographic comparison Exhibit 49: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 UK - Market size and forecast 2021-2026 Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.10 Canada - Market size and forecast 2021-2026 Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.11 China - Market size and forecast 2021-2026 Exhibit 82: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 83: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 84: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 85: Data Table on China - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 86: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 87: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 88: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 89: Overview on factors of disruption 9.4 Industry risks Exhibit 90: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 91: Vendors covered 10.2 Market positioning of vendors Exhibit 92: Matrix on vendor position and classification 10.3 Akebia Therapeutics Inc. Exhibit 93: Akebia Therapeutics Inc. - Overview Exhibit 94: Akebia Therapeutics Inc. - Product / Service Exhibit 95: Akebia Therapeutics Inc. - Key offerings 10.4 Amgen Inc. Exhibit 96: Amgen Inc. - Overview Exhibit 97: Amgen Inc. - Product / Service Exhibit 98: Amgen Inc. - Key offerings 10.5 Biocon Ltd. Exhibit 99: Biocon Ltd. - Overview Exhibit 100: Biocon Ltd. - Business segments Exhibit 101: Biocon Ltd. - Key offerings Exhibit 102: Biocon Ltd. - Segment focus 10.6 Biosidus SA Exhibit 103: Biosidus SA - Overview Exhibit 104: Biosidus SA - Product / Service Exhibit 105: Biosidus SA - Key offerings 10.7 F. Hoffmann La Roche Ltd. Exhibit 106: F. Hoffmann La Roche Ltd. - Overview Exhibit 107: F. Hoffmann La Roche Ltd. - Business segments Exhibit 108: F. Hoffmann La Roche Ltd. - Key news Exhibit 109: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 110: F. Hoffmann La Roche Ltd. - Segment focus 10.8 Johnson and Johnson Exhibit 111: Johnson and Johnson - Overview Exhibit 112: Johnson and Johnson - Business segments Exhibit 113: Johnson and Johnson - Key news Exhibit 114: Johnson and Johnson - Key offerings Exhibit 115: Johnson and Johnson - Segment focus 10.9 Nanogen Pharmaceutical Biotechnology Exhibit 116: Nanogen Pharmaceutical Biotechnology - Overview Exhibit 117: Nanogen Pharmaceutical Biotechnology - Product / Service Exhibit 118: Nanogen Pharmaceutical Biotechnology - Key offerings 10.10 Novartis AG Exhibit 119: Novartis AG - Overview Exhibit 120: Novartis AG - Business segments Exhibit 121: Novartis AG - Key offerings Exhibit 122: Novartis AG - Segment focus 10.11 Pfizer Inc. Exhibit 123: Pfizer Inc. - Overview Exhibit 124: Pfizer Inc. - Product / Service Exhibit 125: Pfizer Inc. - Key news Exhibit 126: Pfizer Inc. - Key offerings 10.12 Thermo Fisher Scientific Inc. Exhibit 127: Thermo Fisher Scientific Inc. - Overview Exhibit 128: Thermo Fisher Scientific Inc. - Business segments Exhibit 129: Thermo Fisher Scientific Inc. - Key news Exhibit 130: Thermo Fisher Scientific Inc. - Key offerings Exhibit 131: Thermo Fisher Scientific Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 132: Inclusions checklist Exhibit 133: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 134: Currency conversion rates for US$ 11.4 Research methodology Exhibit 135: Research methodology Exhibit 136: Validation techniques employed for market sizing Exhibit 137: Information sources 11.5 List of abbreviations Exhibit 138: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 Deals associated with Epoetin beta biosimilar(Abbott Laboratories)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B03XA01	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia	-	Abbott Laboratories	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2007	Not Applicable	Anemia \| Neoplasms	100	Darbepoetin alfa every three weeks	wylyoowsdw(njrazotlmw) = tilwlozzmr ogdaezsfny (aosuqdbnec )	-	20 Jun 2007
				Epoetin thrice weekly	wylyoowsdw(njrazotlmw) = cqswqrveek ogdaezsfny (aosuqdbnec )
ASCO2006	Not Applicable	Anemia	110	Darbepoetin alfa	phupppnfhx(ecynuervox) = uqqsagenwx alqrofiaqn (movxbdwupr )	Positive	20 Jun 2006
				Epoetin	phupppnfhx(ecynuervox) = luvcpwusgs alqrofiaqn (movxbdwupr )
ASCO2005	Not Applicable	Anemia \| Ovarian Cancer	120	Epoetin beta 150 IU/kg	wkfaachsnl(ezlwvihhyd) = mbhastuucx tgibdsczuf (dvhwadynag )	-	01 Jun 2005
				No epoetin	wkfaachsnl(ezlwvihhyd) = fdqvvddllz tgibdsczuf (dvhwadynag )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis